Page URL:

FDA advisors back gene therapy for rare inherited blindness

16 October 2017
Appeared in BioNews 922

The US Food Drug and Administration (FDA) advisory committee has backed the use of gene therapy to treat a hereditary disease for the first time.

Luxturna has been tested to treat patients who have inherited retinal dystrophy, a disease caused when both copies of the RPE65 gene carry a mutation. The eyes' ability to respond to light is increasingly impaired and patients eventually become blind.

'This would be the first approved treatment of any sort for this condition and the first approved gene therapy treatment for the eye, in general,' Dr Paul Yang of Oregon Health and Science University told National Public Radio. 'So, on multiple fronts, it's a first and ushers in a new era of gene therapy', he added.

In a clinical trial of 31 people, sponsored by Spark Therapeutics and led by Professor Albert Maguire of the University of Pennsylvania, Luxturna significantly improved the visual outcome in people aged between four to 44 years old who received the drug as a one-time sub-retinal injection, compared to a control group.

The injection consisted of a genetically engineered adeno-associated viral vector, which contained the normal copy of the RPE65 gene. When injected into the retinal cells, the gene expressed the RPE65 protein: a vital enzyme for normal retinal function.

The effectiveness of the therapy was determined by using a novel approach: multi-luminance mobility testing, which assesses how well a person is able to navigate and move under different light levels. At one year post-treatment, those who had received treatment showed improved visual acuity, compared to the control group.

However, there were a few complications, including events related to the procedure and permanent retinal damage caused by use of prednisone medication. Taking into consideration, all 16 members of The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) decided the efficacy data outweighed the safety risks, and gave favourable recommendation to the FDA to approve Luxturna.

In most cases, the FDA follows the recommendations set by advisory committee but there is currently a series of unanswered questions, as outlined in the FDA briefing document. These include: 'what additional data, if any, would be necessary to support such repeat administration?' and, 'at what stage of clinical presentation do the benefits of therapy outweigh the risks?'

Furthermore, the long-term effects of the treatment are unknown. Speaking to NatureProfessor Mark Kay, a geneticist at Stanford University, California, said: 'I think we still need to have major improvements in the technology before we're going to be able to cure these diseases, but along the way there may be treatments that help make improvements'.

A decision from the FDA on Luxturna is expected by early next year.

FDA advisers back gene therapy for rare form of blindness
Nature |  12 October 2017
FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec)
Global Newswire |  12 October 2017
FDA Briefing Document - Voretigene Neparvovec
FDA |  12 October 2017
FDA Panel Endorses Gene Therapy For A Form Of Childhood Blindness
npr |  12 October 2017
FDA Vote Sets Stage for Gene Therapy’s Future
MIT Technology Review |  12 October 2017
9 September 2019 - by Jen Willows 
An in-body gene therapy treatment has been approved to treat a rare genetic form of blindness...
15 July 2019 - by Charlotte Spicer 
The first RNA-based therapy has been approved for NHS use in England...
3 September 2018 - by Dr Charlott Repschlager 
Dogs with Duchenne muscular dystrophy (DMD) have been treated using genome editing, a study in Science reports...
27 November 2017 - by Theofanis Michailidis 
The US Food and Drug Administration (FDA) is taking an active stance against the use of 'do it yourself' gene therapy kits...
20 November 2017 - by Martha Henriques 
The US Food and Drug Administration has announced a fast-track review process for gene therapies and other regenerative medicine treatments...
9 October 2017 - by Dr Kimberley Bryon-Dodd 
Gene therapy has restored some vision in mice blinded by retinitis pigmentosa, an inherited degenerative eye disease...
3 May 2016 - by Sarah Gregory 
A trial of gene therapy for choroideremia, a rare form of inherited blindness, has partially restored the vision of several patients...
24 August 2015 - by Antony Starza-Allen 
An experimental form of gene therapy to treat blindness has been showed to restore some vision in mice....
15 December 2014 - by Dr Rosie Morley 
Scientists have used gene therapy to restore some sight to animals with visual impairment similar to retinosa pigmentosa, a type of human blindness...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.